CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Lenalidomide 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928486
NCT00928486Phase 3Completed
CompareCT.gov

A Safety Confirmation Study On Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

Celgene·interventional·Posted Jun 26, 2009·Updated Nov 20, 2019

In Brief

A Phase 3 clinical trial evaluating Lenalidomide and Dexamethasone for Multiple Myeloma. Completed, enrolled 25 participants across 8 sites.

Detailed Summary

To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 26, 2009
Enrollment StartApr 28, 2009
Primary CompletionSep 10, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.0 years ago

Interventions

Lenalidomidedrug

Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle

Dexamethasonedrug

Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle